检索结果-南通市图书馆

Frontiers of Agricultural Science and Engineering 2015年第3期2卷 216-222页

作者： Yuzhou WANG Tongyan WANG He YAN Fanli YANG Linghua GUO Qingyuan YANG Xule HU Feifei TAN Yan XIAO Xiangdong LI Kegong TIAN National Research Center for Veterinary Medicine Luoyang 471003China College of Animal Science and Veterinary Medicine Henan Agricultural UniversityZhengzhou 450002China

Pseudorabies(PR)is a devastating viral disease which leads to fatal encephalitis and respiratory disorders in pigs.Commercial gE-deleted live pseudorabies virus(PRV)vaccine has been widely used to control this disease in China.However,the new-emerging variants of PRV compromises the protection provided by current vaccines and lead to the outbreak of PR in vaccinated pig herds.Several killed and live vaccine candidates based on current PRV variants have been reported to be effective to control the disease.A subunit vaccine based on gB protein,one major PRV glycoprotein which elicits strong humoral and cellular immune responses,however,was never evaluated for protection against the current circulating PRV variants.In this study,full-length PRV gB protein was successfully expressed in baculovirus/insect cells in the soluble format and was tested on 3-week-old piglets as a subunit vaccine.Compared with unvaccinated pigs,the gB-vaccinated pigs developed specific antibody-mediated responses and were protected from the virulent PRV HN1201 challenge.All vaccinated pigs survived without showing any PRV-specific respiratory and neurological signs,but all unvaccinated pigs died within 7 days after HN1201 challenge.Hence,this novel gB-based vaccine could be applied as an effective subunit vaccine to control PRV variant in China.

关键词： pseudorabies virus glycoprotein B protein subunit vaccine

Analysis of the immunogenicity and bioactivities of a Mycoplasma pneumoniae subunit vaccine mixed with different adjuvant in BALB/c mice

在线全文

学校读者我要写书评

暂无评论

Analysis of the immunogenicity and bioactivities of a Mycopl...

The Adjuvant Effect of Rapamycin for a New Multi-stage subunit vaccine Candidate LT69

中国生物化学与分子生物学会2016年全国学术会议

作者： GUO Jun LUO Xiao QI Yong LI Yue-xi Hua Dong Institute of Medical and Pharmaceutical Biotechnology School of Chinese Medicine

Objective Indentifying effective adjuvants,immunity dose and procedure for the mycoplasma pneumoniae(MP)subunit vaccine in BALB/c mice.Methods Groups(n=16)of female 6-week-old BALB/c mice were immunized with vaccine a... 详细信息

关键词： Mycoplasma pneumoniae subunit vaccine MP559

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

The Adjuvant Effect of Rapamycin for a New Multi-stage Subun...

Protection against lethal subcutaneous challenge of virulent Y. pestis strain 141 using an F1-V subunit vaccine

第十届全国免疫学学术大会

作者： Hongxia Niu Chunxiang Bai Bingdong Zhu Lanzhou Center for Tuberculosis Research and Institute of Pathogenic Biology & Gansu Provincial Key Laboratory of Evidence Based Medicine and Clinical Translation School of Basic Medical Sciences Lanzhou University

Objective:Tuberculosis(TB)remains a major global health problem and ranks as the second leading cause of deathfrom an infectious disease worldwide.Mycobacterium bovis Bacillus Calmette-Gue is the only tuberculosis vaccine for human use in current,but its protective efficacy wanes significantly over a period of 10-15 years or less.we need to seek some strategies to provide long-term protective immunity to TB.There are several factors which are related to the establishment and maintenance of memory T cell responses,such as antigen dose,other immune regulators including drug rapamycin.Thus,we applied rapamycin as the adjuvant.Method:The mice inoculated with LT69 at the 0,14th and 28th day were additional treated with rapamycin with two different strategies:(1)At the T cell expansion phases during vaccination(from day-1 prior to injection to day 8 postLT69 first immunization;the second 8 days after the second time LT69 immunization,from day 14 to day 22;the third 8days,from day 28 to day 36).(2)At the T cell expansion phases as described above and the T cell contraction phase after the last immunization(from day 36 to day 54).Rapamycin was delivered by i.***.injection and the daily dose was 75μg/kg.The mice were injected with LT69 vaccine alone,PBS or BCG were as controls.24 weeks after the last time vaccination,the IFN-γwas tested using ELISPOT assay.For the protective efficacy evaluation,the mice were challenged with Mycobacterium bovis attenuated strain BCG by the caudal vein injection and the CFUs of bacteria in infected lungs were assayed 3 weeks later.The bacteria was verified by the acid-fast stain.Results:Rapamycin treatment during LT69 vaccination increased the expression of antigens specific IFN-γ(pvaccine long-term protective efficacy(pvaccine-induced immune memory response and long-term protective efficacy.

关键词： Tuberculosis subunit vaccine Rapamycin Immune Memory

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

Science China(Life Sciences) 2007年第5期50卷 600-604页

作者： WANG Dong JIA Nuan LI Peng XING Li WANG XiLiang Institute of Microbiology and Epidemiology State Key Laboratory of Pathogen and BiosecurityAcademy of Military Medical Sci-encesBeijing 100071China School of Pharmacy Second Military Medical UniversityShanghai 200433China Hospital Attached to Aeromedicine Institute of PLA Beijing 100089China

In this study, we designed and engineered a two-component recombinant fusion protein antigen as a vaccine candidate against the possible biological threat of Yersinia pestis. The recombinant F1-V pro-tein was formulated with Alhydrogel. A four-time injection with a dosage of 10, 20 and 50 μg/mouse in about two months was adopted for vaccination. Serum antibodies and subclass of T helper cells were measured and analyzed. After the final vaccination, the mice were challenged by 141 strain with 25― 600 LD50. In conclusion, the recombinant vaccine was capable of inducing protective immunity against subcutaneous challenge. The level of serum IgG was supposed to be a main factor that affected the final protection of challenge. 20 μg recombinant protein could induce an endpoint titre of serum IgG as high as 51200, which was enough to afford 100% protection against 400 LD50 virulent 141 challenge. The antibody isotype analysis showed that the vaccine induced predominantly an IgG1 rather than IgG2a response. Flow cytometric analysis revealed that Alhydrogel significantly helped induce a stronger humoral immunity instead of CTL cellular response. These findings suggested that the plague F1-V subunit vaccine is promising for the next plague vaccine.

关键词： Yersinia pestis F1-V fusion protein challenge subunit vaccine

SpyStapler-mediated assembly of nanoparticle vaccines

在线全文

学校读者我要写书评

暂无评论

Nano Research 2023年第2期16卷 2821-2828页

作者： Songzi Kou Weitao Chen Chenbo Sun Fei Sun Biomedical Research Institute Shenzhen Peking University-The Hong Kong University of Science and Technology Medical CenterShenzhen 518036China Greater Bay Biomedical Innocenter Shenzhen Bay LaboratoryShenzhen 518132China Department of Chemical and Biological Engineering The Hong Kong University of Science and TechnologyClear Water BayKowloonHong KongChina

The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has wreaked havoc around the globe,with no end in sight.The rapid emergence of viral mutants,marked by rapid transmission and effective immune evasion,has also posed unprecedented challenges for vaccine development,not least in its speed,mass production,and distribution.Here we report a versatile“plug-and-display”strategy for creating protein vaccines,including those against malaria parasites and SARS-CoV-2,through the combined use of the intrinsically disordered protein ligase SpyStapler and computationally designed viral-like particles.The resulting protein nanoparticles harboring multiple antigens induce potent neutralizing antibody responses in mice,substantially stronger than those induced by the corresponding free antigens.This modular vaccine design enabled by SpyStapler furnishes us with a new weapon for combatting infectious diseases.

关键词： subunit vaccine SpyTag SARS-CoV-2 malaria

LNP-CpG ODN-adjuvanted varicella-zoster virus glycoprotein E induced comparable levels of immunity with Shingrix^(TM) in VZV-primed mice

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Virologica Sinica 2022年第5期37卷 731-739页

作者： Ning Luan Han Cao Yunfei Wang Kangyang Lin Cunbao Liu Institute of Medical Biology Chinese Academy of Medical Sciences and Peking Union Medical CollegeKunming 650118China

Latent varicella-zoster virus(VZV)may be reactivated to cause herpes zoster,which affects one in three people during their lifetime.The currently available subunit vaccine Shingrix^(TM) is superior to the attenuated vaccine Zostavax®in terms of both safety and efficacy,but the supply of its key adjuvant component QS21 is limited.With ionizable lipid nanoparticles(LNPs)that were recently approved by the FDA for COVID-19 mRNA vaccines as carriers,and oligodeoxynucleotides containing CpG motifs(CpG ODNs)approved by the FDA for a subunit hepatitis B vaccine as immunostimulators,we developed a LNP vaccine encapsulating VZV-glycoprotein E(gE)and CpG ODN,and compared its immunogenicity with Shingrix^(TM) in C57BL/6J mice.The results showed that the LNP vaccine induced comparable levels of gE-specific IgG antibodies to Shingrix^(TM) as determined by enzymelinked immunosorbent assay(ELISA).Most importantly,the LNP vaccine induced comparable levels of cellmediated immunity(CMI)that plays decisive roles in the efficacy of zoster vaccines to Shingrix^(TM) in a VZVprimed mouse model that was adopted for preclinical studies of Shingrix^(TM) .Number of IL-2 and IFN-γsecreting splenocytes and proportion of T helper 1(Th1)cytokine-expressing CD4^(+)T cells in LNP-CpG-adjuvanted VZV-gE vaccinated mice were similar to that of Shingrix^(TM) boosted mice.All of the components in this LNP vaccine can be artificially and economically synthesized in large quantities,indicating the potential of LNP-CpGadjuvanted VZV-gE as a more cost-effective zoster vaccine.

关键词： Varicella zoster virus(VZV) subunit vaccine Adjuvant Lipid nanoparticle(LNP) CpG oligodeoxynucleotide(CpG ODN) AS01B Humoral immunity Cell-mediated immunity(CMI)

Protective efficacy evaluation of immunogenic protein AHA_3793 of Aeromonas hydrophila as vaccine candidate for largemouth bass Micropterus salmoides

在线全文

学校读者我要写书评

暂无评论

Journal of Oceanology and Limnology 2023年第1期41卷 392-400页

作者： Shun YANG Idefonce MKINGULE Long LIU Wenqi CHEN Xiangyu YUAN Zixuan MA Liang LIANG Shichao QIAN Mengmeng HUANG Hui FEI College of Life Sciences and Medicine Zhejiang Sci-Tech UniversityHangzhou 310018China Zhejiang Development&Planning Institute Hangzhou 310012China Huzhou Baijiayu Biotech Co. Ltd.Huzhou 313000China

Aeromonas hydrophila is a Gram-negative pathogen that can infect various fish,including largemouth bass(Micropterus salmoides),which have caused huge economic losses.In present study,largemouth bass anti-A.hydrophila antibodies were produced,then a highly immunogenic outer membrane proteins,AHA_3793,was identified by combined western blotting and mass spectrometry analysis.Moreover,AHA_3793 was expressed,and its immunogenicity was further verified by western blotting.Subsequently,the protective efficacy of AHA_3793 were evaluated in largemouth bass.The results showed that rAHA_3793 could produce a relative percentage survival(RPS)of 61.76% for largemouth bass against A.hydrophila challenge.ELISA analysis showed the specific serum antibodies of largemouth bass against rAHA_3793 and A.hydrophila in vaccinated group in weeks 4 and 5 after immunization were significantly higher than those in control group,which suggested that rAHA_3793 induced production of specific serum antibodies against rAHA_3793 and A.hydrophila.The qRT-PCR analysis showed that expressions of CD4-2 and MHC Ⅱα were also significantly up-regulated after immunization.These results collectively demonstrated that rAHA_3793 could induce a strong humoral immune response of largemouth bass,and then produce high immune protection ef fects against A.hydrophila infection.

关键词： Micropterus salmoides Aeromonas hydrophila AHA_3793 subunit vaccine immune response

A recombinant receptor-binding domain in trimeric form generates protective immunity against SARSCoV-2 infection in nonhuman primates

在线全文

学校读者我要写书评

暂无评论

The Innovation 2021年第3期2卷 94-102页

作者： Limin Yang Deyu Tian Jian-bao Han Wenhui Fan Yuan Zhang Yunlong Li Wenqiang Sun Yanqiu Wei Xiaodong Tian Dan-dan Yu Xiao-li Feng Gong Cheng Yuhai Bi Yong-tang Zheng Wenjun Liu CAS Key Laboratory of Pathogenic Microbiology and Immunology Institute of MicrobiologyCenter for Influenza Research and Early Warning(CASCIRE)CAS-TWAS Center of Excellence for Emerging Infectious Diseases(CEEID)Chinese Academy of SciencesBeijing 100101China University of Chinese Academy of Sciences Beijing 101408China Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences Kunming Institute of ZoologyChinese Academy of SciencesKunming 650223China Kunming National High-Level Biosafety Research Center for Nonhuman Primates Center for Biosafety Mega-ScienceKunming Institute of ZoologyChinese Academy of SciencesKunming 650107China Institute of Infectious Diseases Shenzhen Bay LaboratoryShenzhen 518000China Tsinghua-Peking Center for Life Sciences School of MedicineTsinghua UniversityBeijing 100084China

A safe and effective vaccine is critical to combat the COVID-19 pandemic.Here,we developed a trimeric SARS-CoV-2 receptor-binding domain(RBD)subunit vaccine candidate that simulates the natural structure of the spike(S)trimer glycoprotein.Immunization with the RBD trimer-induced robust humoral and cellular immune responses,and a high level of neutralizing antibodies was maintained for at least 4.5 months.Moreover,the antibodies that were produced in response to the vaccine effectively cross-neutralized the SARS-CoV-2501Y.V2 variant(B.1.351).Of note,when the vaccine-induced antibodies dropped to a sufficiently low level,only one boost quickly activated the anamnestic immune response,conferring full protection against a SARSCoV-2 challenge in rhesus macaques without typical histopathological changes in the lung tissues.These results demonstrated that the SARS-CoV-2 RBD trimer vaccine candidate is highly immunogenic and safe,providing long-lasting,broad,and significant immunity protection in nonhuman primates,thereby offering an optimal vaccination strategy against COVID-19.

关键词： COVID-19 SARS-CoV-2 RBD subunit vaccine NHPs variants

Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cellular & Molecular Immunology 2016年第2期13卷 180-190页

作者： Naru Zhang Rudragouda Channappanavar Cuiqing Ma Lili Wang Jian Tang Tania Garron Xinrong Tao Sumaiya Tasneem Lu Lu Chien-Te K Tseng Yusen Zhou Stanley Perlman Shibo Jiang Lanying Du Lindsley F. Kimball Research Institute New York Blood Center New York NY USA Department of Microbiology University of Iowa Iowa City IA USA State Key Laboratory of Pathogen and Biosecurity Beijing Institute of Microbiology and Epidemiology Beijing China Department of Microbiology and Immunology and Center for Biodefense and Emerging Disease University of Texas Medical Branch Galveston TX USA Key Laboratory of Medical Molecular Virology of Ministries of Education and Health Shanghai Medical College and Institute of Medical Microbiology Fudan University Shanghai China Xiang-Ya Medical College Central South University Changsha. China

Middle East respiratory syndrome （MERS）, an emerging infectious disease caused by MERS coronavirus （MERS-CoV）, has garnered worldwide attention as a consequence of its continuous spread and pandemic potential, making the development of effective vaccines a high priority. We previously demonstrated that residues 377-588 of MERS-CoV spike （S） protein receptor-binding domain （RBD） is a very promising MERS subunit vaccine candidate, capable of inducing potent neutralization antibody responses. In this study, we sought to identify an adjuvant that optimally enhanced the immunogenicity of S377-588 protein fused with Fc of human IgG （S377-588-Fc）. Specifically, we compared several commercially available adjuvants, including Freund＇s adjuvant, aluminum, Monophosphoryl lipid A, Montanide ISA51 and MF59 with regard to their capacity to enhance the immunogenicity of this subunit vaccine. In the absence of adjuvant, S377-588-Fc alone induced readily detectable neutralizing antibody and T-cell responses in immunized mice. However, incorporating an adjuvant improved its immunogenicity. Particularly, among the aforementioned adjuvants evaluated, MF59 is the most potent as judged by its superior ability to induce the highest titers of IgG, IgG1 and IgG2a subtypes, and neutralizing antibodies. The addition of MF59 significantly augmented the immunogenicity of S377-588-Fcto induce strong IgG and neutralizing antibody responses as well as protection against MERS-CoV infection in mice, suggesting that MF59 is an optimal adjuvant for MERS-CoV RBD-based subunit vaccines.

关键词： adjuvant effects MERS MERS-CoV receptor-binding domain subunit vaccine

Vaccination of Goats with 31 kDa and 32 kDa Schistosoma japonicum Antigens by DNA Priming and Protein Boosting

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cellular & Molecular Immunology 2007年第2期4卷 153-156页

作者： Lianfei Tang Zhijun Zhou Yuxiao Chen Yonghui Luo Linqian Wang Liyu Chen Fushen Huang Xianfang Zeng Xinyuan Yi Hunan Entry-Exit Inspection and Quarantine Bureau of the People＇s Republic of China Changsha 410007 Hunan China Department of Parasitology Xiangya School of Medicine Central South University Changsha 410078 Hunan China Department of Laboratory Animal Xiangya School of Medicine Central South University Changsha 410078 Hunan China College of Animal Science Hunan Agriculture University Changsha 410128 Hunan China

Two Schistosomajaponicum vaccine candidate antigens Sj 31 and Sj 32, which have shown particular promise to induce protective immunity in mice, were used to immunize goats by using a DNA priming-protein boosting strategy in present work. DNA vaccine formulations of the two antigens （VRSj31 and VRSj32） were produced and injected intramuscularly twice at a 2-week interval and then recombinant proteins （rSj31 and rSj32） together with Freund Complete Adjuvant （FCA） were used to boost the goats. The experiment was repeated in different batche cercariae. A strong anamnestic antibody response was induced after boost. A significant reduction of liver egg counts and miracidial hatching was showed in both experiments. Significant protections against challenge infection were elicited with 31.6% of percentage reduction for worm recovery in the second experiment and 20.9% in the first experiment, respectively.

关键词： subunit vaccine DNA vaccine Schistosoma japonicum